Stock Taper 
Coherus Oncology develops and commercializes immunotherapies and biosimilars for cancer and inflammatory diseases, with collaborations and licensing agreements worldwide.
LOQTORZI, FDA-approved in October 2023 as the first treatment for recurrent or metastatic nasopharyngeal carcinoma, marks Coherus' strategic shift from biosimilars to a leading immuno-oncology franchise.
In April 2025, Coherus completed the sale of its UDENYCA® franchise to Intas Pharmaceuticals for a significant upfront cash payment, fundamentally shifting its focus to oncology. This strategic move was followed by a company name change to Coherus Oncology, Inc. in May 2025 and a significant restructuring, including a 30% reduction in its workforce, to align with its new oncology-centric strategy.
Coherus completed the sale of its UDENYCA® (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals. This divestiture marks the final step in the company's multi-year transition away from biosimilars to focus exclusively on its innovative immuno-oncology pipeline, including its approved PD-1 inhibitor LOQTORZI® and other clinical-stage candidates.
Molecular Partners (NASDAQ: MOLN - Get Free Report) and Coherus Oncology (NASDAQ: CHRS - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Earnings and Valuation This table compares Molecular
Coherus Oncology (NASDAQ: CHRS - Get Free Report) and Emergent Biosolutions (NYSE: EBS - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a breakdown of
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
 SLS | $11.60 | COMPARE |
 AVTX | $14.59 | COMPARE |
 OABI | $4.90 | COMPARE |
 CCCC | $3.02 | COMPARE |
 IVVD | $0.81 | COMPARE |
 CDXS | $1.40 | COMPARE |
 TARA | $2.60 | COMPARE |
 IMDX | $3.52 | COMPARE |
